{"title":"The Potential Benefits of Akkermansia muciniphila as a Next-Generation Probiotic in the Maintenance of Overall Liver Health.","authors":"K Rachwal, K Mierczak, T Poplawski","doi":"10.51821/88.1.13037","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and study aim: </strong>The gut-liver axis and gut microbiota, with a particular focus on Akkermansia muciniphila, a next-generation probiotic, have been identified as significant factors in preventing the development and progression of liver diseases. This review aims to discuss the potential therapeutic role of A. muciniphila in maintaining liver health, focusing on the latest findings from preclinical and clinical studies.</p><p><strong>Methods: </strong>To achieve the review's purpose, the most common keywords were searched in three online databases (PubMed, bioRxiv, and Google Scholar).</p><p><strong>Results: </strong>The search approach identified 49 references. Studies have shown that the gut microbiota, including A. muciniphila, has the potential to be a therapeutic target for many hepatic disorders. Several studies have demonstrated A. muciniphila's beneficial effects on improving metabolic parameters, including insulin resistance, blood cholesterol levels, and overall liver function.</p><p><strong>Conclusions: </strong>Further research is necessary to determine the optimal dosage, duration, and administration route of A. muciniphila for managing hepatic disorders. While there are promising findings, a more thorough understanding of the underlying mechanisms and the development of effective therapeutic strategies are necessary for successful treatment of liver diseases.</p>","PeriodicalId":7322,"journal":{"name":"Acta gastro-enterologica Belgica","volume":"88 2","pages":"141-150"},"PeriodicalIF":1.3000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta gastro-enterologica Belgica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.51821/88.1.13037","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background and study aim: The gut-liver axis and gut microbiota, with a particular focus on Akkermansia muciniphila, a next-generation probiotic, have been identified as significant factors in preventing the development and progression of liver diseases. This review aims to discuss the potential therapeutic role of A. muciniphila in maintaining liver health, focusing on the latest findings from preclinical and clinical studies.
Methods: To achieve the review's purpose, the most common keywords were searched in three online databases (PubMed, bioRxiv, and Google Scholar).
Results: The search approach identified 49 references. Studies have shown that the gut microbiota, including A. muciniphila, has the potential to be a therapeutic target for many hepatic disorders. Several studies have demonstrated A. muciniphila's beneficial effects on improving metabolic parameters, including insulin resistance, blood cholesterol levels, and overall liver function.
Conclusions: Further research is necessary to determine the optimal dosage, duration, and administration route of A. muciniphila for managing hepatic disorders. While there are promising findings, a more thorough understanding of the underlying mechanisms and the development of effective therapeutic strategies are necessary for successful treatment of liver diseases.
期刊介绍：
The Journal Acta Gastro-Enterologica Belgica principally publishes peer-reviewed original manuscripts, reviews, letters to editors, book reviews and guidelines in the field of clinical Gastroenterology and Hepatology, including digestive oncology, digestive pathology, as well as nutrition. Pure animal or in vitro work will not be considered for publication in the Journal. Translational research papers (including sections of animal or in vitro work) are considered by the Journal if they have a clear relationship to or relevance for clinical hepato-gastroenterology (screening, disease mechanisms and/or new therapies). Case reports and clinical images will be accepted if they represent an important contribution to the description, the pathogenesis or the treatment of a specific gastroenterology or liver problem. The language of the Journal is English. Papers from any country will be considered for publication. Manuscripts submitted to the Journal should not have been published previously (in English or any other language), nor should they be under consideration for publication elsewhere. Unsolicited papers are peer-reviewed before it is decided whether they should be accepted, rejected, or returned for revision. Manuscripts that do not meet the presentation criteria (as indicated below) will be returned to the authors. Papers that go too far beyond the scope of the journal will be also returned to the authors by the editorial board generally within 2 weeks. The Journal reserves the right to edit the language of papers accepted for publication for clarity and correctness, and to make formal changes to ensure compliance with AGEB’s style. Authors have the opportunity to review such changes in the proofs.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
